These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11719361)

  • 1. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.
    Barosi G; Viarengo G; Pecci A; Rosti V; Piaggio G; Marchetti M; Frassoni F
    Blood; 2001 Dec; 98(12):3249-55. PubMed ID: 11719361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
    Passamonti F; Vanelli L; Malabarba L; Rumi E; Pungolino E; Malcovati L; Pascutto C; Morra E; Lazzarino M; Cazzola M
    Haematologica; 2003 Oct; 88(10):1123-9. PubMed ID: 14555308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia.
    Massa M; Rosti V; Ramajoli I; Campanelli R; Pecci A; Viarengo G; Meli V; Marchetti M; Hoffman R; Barosi G
    J Clin Oncol; 2005 Aug; 23(24):5688-95. PubMed ID: 16110028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia.
    Barosi G; Rosti V; Massa M; Viarengo GL; Pecci A; Necchi V; Ramaioli I; Campanelli R; Marchetti M; Bazzan M; Magrini U
    Br J Haematol; 2004 Mar; 124(5):618-25. PubMed ID: 14871248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia.
    Rosti V; Massa M; Vannucchi AM; Bergamaschi G; Campanelli R; Pecci A; Viarengo G; Meli V; Marchetti M; Guglielmelli P; Bruno E; Xu M; Hoffman R; Barosi G; ;
    Blood Cells Mol Dis; 2007; 38(3):280-6. PubMed ID: 17350297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients.
    Arora B; Sirhan S; Hoyer JD; Mesa RA; Tefferi A
    Br J Haematol; 2005 Jan; 128(1):42-8. PubMed ID: 15606548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study.
    Orvain C; Luque Paz D; Dobo I; Cottin L; Le Calvez G; Chauveau A; Mercier M; Farhi J; Boyer F; Ianotto JC; Guibourg B; Rousselet MC; Zandecki M; Ifrah N; Hunault-Berger M; Ugo V; Genevieve F
    Ann Hematol; 2016 Oct; 95(11):1819-23. PubMed ID: 27582015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia.
    Le Bousse-Kerdilès MC; Chevillard S; Charpentier A; Romquin N; Clay D; Smadja-Joffe F; Praloran V; Dupriez B; Demory JL; Jasmin C; Martyré MC
    Blood; 1996 Dec; 88(12):4534-46. PubMed ID: 8977245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.
    Le Bousse-Kerdilès MC; Martyré MC
    Ann Hematol; 1999 Oct; 78(10):437-44. PubMed ID: 10550553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression.
    Panteli K; Zagorianakou N; Bai M; Katsaraki A; Agnantis NJ; Bourantas K
    Eur J Haematol; 2004 Jun; 72(6):410-5. PubMed ID: 15128419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow CD34+ progenitor cells in Philadelphia chromosome-negative chronic myeloproliferative disorders--a clinicopathological study on 575 patients.
    Thiele J; Kvasnicka HM; Diehl V
    Leuk Lymphoma; 2005 May; 46(5):709-15. PubMed ID: 16019508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
    Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A
    Leuk Lymphoma; 2002 Dec; 43(12):2301-7. PubMed ID: 12613516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis.
    Emadi S; Clay D; Desterke C; Guerton B; Maquarre E; Charpentier A; Jasmin C; Le Bousse-Kerdilès MC;
    Blood; 2005 Jan; 105(2):464-73. PubMed ID: 15454487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups.
    Cervantes F; Barosi G; Demory JL; Reilly J; Guarnone R; Dupriez B; Pereira A; Montserrat E
    Br J Haematol; 1998 Aug; 102(3):684-90. PubMed ID: 9722294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered transcription of the stem cell leukemia gene in myelofibrosis with myeloid metaplasia.
    Steunou V; Le Bousse-Kerdilès MC; Colin-Micouin A; Clay D; Chevillard S; Martyré MC;
    Leukemia; 2003 Oct; 17(10):1998-2006. PubMed ID: 14513050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension.
    Popat U; Frost A; Liu E; Guan Y; Durette A; Reddy V; Prchal JT
    Blood; 2006 May; 107(9):3486-8. PubMed ID: 16418333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating hematopoietic progenitor cells predict survival in patients with myelofibrosis with myeloid metaplasia.
    Sagaster V; Jäger E; Weltermann A; Schwarzinger I; Gisslinger H; Lechner K; Geissler K; Oehler L
    Haematologica; 2003 Nov; 88(11):1204-12. PubMed ID: 14607748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.
    Panteli KE; Hatzimichael EC; Bouranta PK; Katsaraki A; Seferiadis K; Stebbing J; Bourantas KL
    Br J Haematol; 2005 Sep; 130(5):709-15. PubMed ID: 16115126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging.
    Cervantes F; Barosi G
    Semin Oncol; 2005 Aug; 32(4):395-402. PubMed ID: 16202685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis.
    Di Raimondo F; Azzaro MP; Palumbo GA; Bagnato S; Stagno F; Giustolisi GM; Cacciola E; Sortino G; Guglielmo P; Giustolisi R
    Leukemia; 2001 Jun; 15(6):976-80. PubMed ID: 11417486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.